In a pooled secondary safety analysis of two phase 3 trials in chronic spontaneous urticaria (912 patients), remibrutinib vs placebo had similar adverse events (64.9% vs 64.7%) but more bleeding (10.6% vs 5.2%), mainly mild petechiae; infections and liver events did not differ.
Meta-analysisn = 912
Giménez-Arnau et al. Safety of Remibrutinib in Chronic Spontaneous Urticaria: A Pooled Analysis of REMIX-1 and REMIX-2 Trials